Kowa Research Institute

CompanyUnited States

Kowa Research Institute develops one asset, in phase 2 (Pemafibrate in primary biliary cholangitis). Mostly small molecule acting on lipid and ceramide metabolism, PPARA and inflammation; based in the United States.

1
Asset
Furthest: Phase 2; 12
Trials: 0
Signals

Pipeline

1

Pemafibrate
Selective peroxisome proliferator-activated receptor alpha (SPPARM-alpha) agonist.
Phase 2, Small molecule, Lipid and ceramide metabolism, PPARA, primary biliary cholangitis

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms4
Trials12
Similar companies6

Updated 8 Oct 2026 · 13 sources